biostudies-literatureVandenHeuvel SNDr. and Mrs. Kaplan Gynecologic Cancer FundTexas A and M Engineering Experiment Station, Texas A and M UniversityNCI NIH HHSNational Institutes of Health7871-7882https://www.ebi.ac.uk/biostudies/studies/S-EPMC11653402biostudies-literatureUnknown7(12)Most ovarian carcinoma (OvCa) patients present with advanced disease at the time of diagnosis. Malignant, metastatic OvCa is invasive and has poor prognosis, exposing the need for improved therapeutic targeting. High CD47 (OvCa) and SIRPα (macrophage) expression has been linked to decreased survival, making this interaction a significant target for therapeutic discovery. Even so, previous attempts have fallen short, limited by CD47 antibody specificity and efficacy. Macrophages are an important component of the OvCa tumor microenvironment and are manipulated to aid in cancer progression via CD47-SIRPα signaling. Thus, we have leveraged lipid-based nanoparticles (LNPs) to design a therapy uniquely situated to home to phagocytic macrophages expressing the SIRPα protein in metastatic OvCa. CDACS applied bio materialsMacrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered <i>In Vitro</i> Models of Ovarian Cancer.PMC11653402R37 CA269224R37CA269224-01A1Mohapatra AChau EGodin BRaghavan SAO'Connell CDabbiru SRoy SVandenHeuvel SNKamat AfalseMacrophage Checkpoint Nanoimmunotherapy Has the Potential to Reduce Malignant Progression in Bioengineered <i>In Vitro</i> Models of Ovarian Cancer.Most ovarian carcinoma (OvCa) patients present with advanced disease at the time of diagnosis. Malignant, metastatic OvCa is invasive and has poor prognosis, exposing the need for improved therapeutic targeting. High CD47 (OvCa) and SIRPα (macrophage) expression has been linked to decreased survival, making this interaction a significant target for therapeutic discovery. Even so, previous attempts have fallen short, limited by CD47 antibody specificity and efficacy. Macrophages are an important component of the OvCa tumor microenvironment and are manipulated to aid in cancer progression via CD47-SIRPα signaling. Thus, we have leveraged lipid-based nanoparticles (LNPs) to design a therapy uniquely situated to home to phagocytic macrophages expressing the SIRPα protein in metastatic OvCa. CD2024-01-01T00:00:00Z2024 Dec2025-04-04T01:54:45.612Z2025-04-04T01:54:45.612ZS-EPMC116534023855843410.1021/acsabm.4c00076